UNSPSC 51401507: Bretazenil

This classification denotes an anxiolytic and anticonvulsant agent with the molecular formula C19H20BrN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OSZ0E9DGOJ, chemically known as 9h-imidazo(1,5-a)pyrrolo(2,1-c)(1,4)benzodiazepine-1-carboxylic acid, 8-bromo-11,12,13,13a-tetrahydro-9-oxo-, 1,1-dimethylethyl ester, (s)- but generally known as bretazenil, which bears US NIH Compound Identifier 107926.

UNSPSC 51401507 Bretazenil, a Commodity code, nominally addresses a specific benzodiazepine pharmaceutical ingredient, but recent state and local solicitation activity under this code shows little direct alignment with bretazenil itself. Instead, the code tags acquisitions for generic multi-source pharmaceuticals, naloxone and drug deactivation systems, and direct-to-manufacturer prescription programs. State and local health departments, cooperative purchasing alliances, and county health systems are the primary issuing bodies, seeking to procure pharmaceutical products and related systems through competitive bidding processes, RFIs, and cooperative contracting vehicles. The work involves sourcing bulk pharmaceutical inventory, establishing pricing agreements with manufacturers and wholesalers, and managing recurring supply contracts with quarterly or annual delivery schedules tied to community health initiatives and government employee benefit programs.

Recent activity spans Florida, Minnesota, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through July 26, 2023 deadline, with quarterly deliveries to the Seminole County Community Health Building in Sanford, and fixed-fee pricing on a two-year contract with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (S1070000015802) in January 2026 with a March 26, 2026 response deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, including Oregon, requiring submission of NDC codes, pricing in multiple formats (FP, net price, WAC-minus), and compliance with cGMP and DSCSA, with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for self-insured employee group health plans, signaling early-stage procurement planning with a formal RFP likely to follow.